Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer.

ABSTRACT:

Purpose

Cabozantinib is a multitargeted tyrosine kinase inhibitor that demonstrated remarkable responses on bone scan in metastatic prostate cancer. Randomized trials failed to demonstrate statistically significant overall survival (OS). We studied the dynamics of biomarker changes with imaging and biopsies pretherapy and posttherapy to explore factors that are likely to be predictive of efficacy with cabozantinib.Experimental Design: Eligibility included patients with metastatic castrate-resistant prostate cancer with normal organ function and performance status 0-2. Cabozantinib 60 mg orally was administered daily. Pretherapy and 2 weeks post, ^99mTc-labeled bone scans, positron emission tomography with ¹⁸F-sodium fluoride (NaF-PET) and ¹⁸F-

SUBMITTER: Vaishampayan UN 

PROVIDER: S-EPMC6335157 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature